As 2023 draws to a close, we look back on some of the major clinical highlights from the year gone by.

In this clinical trial roundup, we present an overview of the ongoing clinical trials involving base-editing therapeutic candidates. This article...

Beam Therapeutics reports dosing of the first patient with BEAM-201, a multiplex-edited allogeneic CAR-T cell candidate developed to treat relapsed or...

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

This week's update features Iovance Biotherapeutics' new cancer immunotherapy candidate IOV-4001 that was recently cleared for clinical trial...

In this piece, we provide selected highlights from the 63rd American Society of Hematology annual meeting, held from December 11-14th 2021.

Some of the best links we picked up around the internet

This week we bring you a clinical trial update on GC027, a CRISPR-edited CAR T-cell therapy for relapsed or refractory CD7+ T cell acute lymphoblastic...